Research on diabetes, including type 1, type 2, and gestational diabetes

From November 2025

Evolocumab significantly reduced cardiovascular events in diabetic patients, ref: Bohula doi.org/10.1056/NEJMoa2514428/
Olezarsen led to greater reductions in triglyceride levels and pancreatitis risk, ref: Marston doi.org/10.1056/NEJMoa2512761/
Semaglutide and tirzepatide showed cardiovascular benefits, but direct comparisons are needed, ref: Krüger doi.org/10.1038/s41591-025-04102-x/
Balcinrenone combined with dapagliflozin improved kidney outcomes in diabetic patients, ref: Heerspink doi.org/10.1016/S0140-6736(25)02014-8/
High-dose oral insulin may prevent type 1 diabetes onset in at-risk children, ref: Ziegler doi.org/10.1016/S0140-6736(25)01726-X/
Real-time continuous glucose monitoring improved pregnancy outcomes in gestational diabetes, ref: Linder doi.org/10.1016/S2213-8587(25)00288-8/
Gut microbiome interactions influence exercise efficacy in diabetes management, ref: Wang doi.org/10.1016/j.cmet.2025.10.013/
High-dose influenza vaccine reduced severe cardiovascular outcomes in older adults, ref: Johansen doi.org/10.1161/CIRCULATIONAHA.125.077801/

Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec